Background
Methods
Patients
Erlotinib administration and laboratory assessment
Statistical analysis
Results
Characteristics | All patients | Lung cancer | Pancreatic cancer | |||
---|---|---|---|---|---|---|
Hepatotoxicity No (%) | Hepatotoxicity No (%) | Hepatotoxicity No (%) | ||||
Presence (n = 62) | Absence (n = 298) | Presence (n = 16) | Absence (n = 139) | Presence (n = 46) | Absence (n = 159) | |
Age (years) | ||||||
< 65 | 28 (45.2) | 155 (52.0) | 6 (37.5) | 85 (61.2) | 22 (47.8) | 70 (44.0) |
≥ 65 | 34 (54.8) | 143 (48.0) | 10 (62.5) | 54 (38.8) | 24 (52.2) | 89 (56.0) |
Sex | ||||||
Male | 35 (56.5) | 182 (61.1) | 8 (50.0) | 87 (62.6) | 27 (58.7) | 95 (59.7) |
Female | 27 (43.5) | 116 (38.9) | 8 (50.0) | 52 (37.4) | 19 (41.3) | 64 (40.3) |
BW (kg) | ||||||
< 60 | 38 (61.3) | 162 (54.4) | 6 (37.5) | 70 (50.4) | 32 (69.6) | 92 (57.9) |
≥ 60 | 24 (38.7) | 136 (45.6) | 10 (62.5) | 69 (49.6) | 14 (30.4) | 67 (42.1) |
Height (cm)a | ||||||
< 160 | 27 (43.5) | 115 (38.7) | 8 (50.0) | 45 (32.4) | 19 (41.3) | 70 (44.3) |
≥ 160 | 35 (56.5) | 182 (61.3) | 8 (50.0) | 94 (67.6) | 27 (58.7) | 88 (55.7) |
BSAb | ||||||
< 1.6 | 32 (51.6) | 130 (43.8) | 5 (31.3) | 54 (38.8) | 27 (58.7) | 76 (48.1) |
≥ 1.6 | 30 (48.4) | 167 (56.2) | 11 (68.6) | 85 (61.2) | 19 (41.3) | 82 (51.9) |
Stagec | ||||||
1–3 | 6 (14.3) | 27 (14.4) | 0 (0.0) | 5 (5.0) | 6 (20.7) | 22 (25.0) |
4 | 36 (85.7) | 161 (85.6) | 13 (100.0) | 95 (95.0) | 23 (79.3) | 66 (75.0) |
CV | ||||||
Yes | 15 (24.2) | 83 (27.9) | 1 (6.3) | 25 (18.0) | 14 (30.4) | 58 (36.5) |
No | 47 (75.8) | 215 (72.1) | 15 (93.8) | 114 (82.0) | 32 (69.6) | 101 (63.5) |
DM | ||||||
Yes | 18 (29.0) | 66 (22.1) | 1 (6.3) | 17 (12.2) | 17 (37.0) | 49 (30.8) |
No | 44 (71.0) | 232 (77.9) | 15 (93.8) | 122 (87.8) | 29 (63.0) | 110 (69.2) |
EGFR mutationsd | ||||||
Yes | 9 (81.8) | 76 (69.1) | 9 (81.8) | 76 (69.1) | NA | NA |
No | 2 (18.2) | 34 (30.9) | 2 (18.2) | 34 (30.9) | NA | NA |
Liver metastasis | ||||||
Yes | 19 (30.6) | 61 (20.5) | 2 (12.5) | 11 (7.9) | 17 (37.0) | 50 (31.4) |
No | 43 (69.4) | 237 (79.5) | 14 (87.5) | 128 (92.1) | 29 (63.0) | 109 (68.6) |
CYP3A4 Inhibitor | ||||||
Yes | 3 (4.8) | 15 (5.0) | 2 (12.5) | 10 (7.2) | 1 (2.2) | 5 (3.1) |
No | 59 (95.2) | 283 (95.0) | 14 (87.5) | 129 (92.8) | 45 (97.8) | 154 (96.9) |
CYP3A4 Inducer | ||||||
Yes | 7 (11.3) | 15 (5.0) | 3 (18.8) | 11 (7.9) | 4 (8.7) | 4 (2.5) |
No | 55 (88.7) | 283 (95.0) | 13 (81.3) | 128 (92.1) | 42 (91.3) | 155 (97.5) |
H2 blocker or PPI | ||||||
Yes | 16 (25.8) | 56 (18.8) | 7 (43.8) | 28 (20.1) | 9 (19.6) | 28 (17.6) |
No | 46 (74.2) | 242 (81.2) | 9 (56.3) | 111 (79.9) | 37 (80.4) | 131 (82.4) |
PPI | ||||||
Yes | 7 (11.3) | 23 (7.7) | 4 (25.0) | 12 (8.6) | 3 (6.5) | 11 (6.9) |
No | 55 (88.7) | 275 (92.3) | 12 (75.0) | 127 (91.4) | 43 (93.5) | 148 (93.1) |
H2 blocker | ||||||
Yes | 9 (14.5) | 41 (13.8) | 3 (18.8) | 22 (15.8) | 6 (13.0) | 19 (11.9) |
No | 53 (85.5) | 257 (86.2) | 13 (81.3) | 117 (84.2) | 40 (87.0) | 140 (88.1) |
Characteristics | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | Attributable risk |
---|---|---|---|
Male | 0.826 (0.475–1.437) | 0.987 (0.516–1.886) | |
Age ≥ 65 | 1.316 (0.760–2.280) | 1.257 (0.718–2.203) | |
BSA ≥ 1.6a | 0.730 (0.422–1.263) | 0.728 (0.383–1.385) | |
Liver metastasis | 1.717 (0.934–3.156) | 1.862 (1.001–3.465)* | 46.3 |
CYP3A4 Inducer | 2.401 (0.936–6.162) | 2.660 (1.013–6.982)* | 62.4 |
Characteristics | Unadjusted OR (95% CI) | Model I | Model II | ||
---|---|---|---|---|---|
Adjusted OR (95% CI) | Attributable risk | Adjusted OR (95% CI) | Attributable risk | ||
Male | 0.598 (0.212–1.688) | 0.251 (0.060–1.048) | 0.266 (0.065–1.084) | ||
Age ≥ 65 | 2.623 (0.902–7.633) | 3.198 (1.023–9.997)* | 68.7 | 3.540 (1.123–11.164)* | 71.8 |
BSA ≥ 1.6 | 1.398 (0.460–4.244) | 3.545 (0.787–15.972) | 3.188 (0.723–14.053) | ||
PPI | 3.528 (0.984–12.651) | 3.529 (0.916–13.595) | |||
H2 blocker or PPI | 3.083 (1.056–9.000)* | 3.454 (1.114–10.713)* | 71.0 |
Characteristics | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
---|---|---|
Male | 0.957 (0.491–1.865) | 1.279 (0.598–2.737) |
Age ≥ 65 | 0.858 (0.444–1.656) | 0.731 (0.369–1.448) |
BSA ≥ 1.6a | 0.652 (0.336–1.268) | 0.549 (0.255–1.180) |
CYP3A4 Inducer | 3.690 (0.886–15.679) | 4.114 (0.969–17.465) |
Characteristics | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
---|---|---|
Male | 0.876 (0.530–1.448) | 1.045 (0.579–1.886) |
Age ≥ 65 | 1.314 (0.797–2.169) | 1.265 (0.764–2.095) |
BSA ≥ 1.6a | 0.795 (0.483–1.309) | 0.771 (0.431–1.377) |
Liver metastasis | 1.897 (1.100–3.275)** | 2.052 (1.179–3.572)* |
CYP3A4 inducer | 2.017 (0.918–4.433) | 2.318 (1.029–5.221)* |